The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases

William K Redekop, Edeltraud J Lenk, Marianne Luyendijk, Christopher Fitzpatrick, Louis Niessen, Wilma A Stolk, Fabrizio Tediosi, Adriana J Rijnsburger, Roel Bakker, Jan A C Hontelez, Jan H Richardus, Julie Jacobson, Sake J de Vlas and Johan L Severens

PLOS Neglected Tropical Diseases, 2017, vol. 11, issue 1, 1-27

Abstract: Background: Lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted helminths (STH) and trachoma represent the five most prevalent neglected tropical diseases (NTDs). They can be controlled or eliminated by means of safe and cost-effective interventions delivered through programs of Mass Drug Administration (MDA)—also named Preventive Chemotherapy (PCT). The WHO defined targets for NTD control/elimination by 2020, reinforced by the 2012 London Declaration, which, if achieved, would result in dramatic health gains. We estimated the potential economic benefit of achieving these targets, focusing specifically on productivity and out-of-pocket payments. Methods: Productivity loss was calculated by combining disease frequency with productivity loss from the disease, from the perspective of affected individuals. Productivity gain was calculated by deducting the total loss expected in the target achievement scenario from the loss in a counterfactual scenario where it was assumed the pre-intervention situation in 1990 regarding NTDs would continue unabated until 2030. Economic benefits from out-of-pocket payments (OPPs) were calculated similarly. Benefits are reported in 2005 US$ (purchasing power parity-adjusted and discounted at 3% per annum from 2010). Sensitivity analyses were used to assess the influence of changes in input parameters. Results: The economic benefit from productivity gain was estimated to be I$251 billion in 2011–2020 and I$313 billion in 2021–2030, considerably greater than the total OPPs averted of I$0.72 billion and I$0.96 billion in the same periods. The net benefit is expected to be US$ 27.4 and US$ 42.8 for every dollar invested during the same periods. Impact varies between NTDs and regions, since it is determined by disease prevalence and extent of disease-related productivity loss. Conclusion: Achieving the PCT-NTD targets for 2020 will yield significant economic benefits to affected individuals. Despite large uncertainty, these benefits far exceed the investment required by governments and their development partners within all reasonable scenarios. Given the concentration of the NTDs among the poorest households, these investments represent good value for money in efforts to share the world’s prosperity and reduce inequity. Author Summary: The five most prevalent neglected tropical diseases (NTDs) are lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted helminths (STH) and trachoma. They can be controlled or eliminated by means of safe and cost-effective interventions delivered through programs of Mass Drug Administration (MDA)—also named Preventive Chemotherapy (PCT).The WHO defined targets for NTD control/elimination by 2020, reinforced by the 2012 London Declaration, which, if achieved, would result in benefits not limited to health gains. We estimated the potential economic benefit of achieving these targets for these NTDs. Economic benefit was calculated by combining the estimated disease frequency with productivity loss resulting from the disease, from the perspective of a person affected by each of the NTDs. The same was done for the healthcare costs paid by the affected individuals. The economic benefit to individuals from productivity gain was estimated to be I$ 251 billion in 2011–2020 (before achieving the targets) and I$ 313 billion in 2021–2030 (after achieving the targets). The estimated total healthcare costs averted are substantial though lower than productivity costs: $0.72 billion in 2011–2020, $0.96 billion in 2021–2030. This would mean a return of US$ 27.4 for each dollar spent between 2015–2020 to reach the targets and US$ 42.8 between 2021–2030. The economic impact varies between NTDs and regions, since it is determined by disease prevalence and the degree of productivity loss caused by the disease.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005289 (text/html)
https://journals.plos.org/plosntds/article/file?id ... 05289&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pntd00:0005289

DOI: 10.1371/journal.pntd.0005289

Access Statistics for this article

More articles in PLOS Neglected Tropical Diseases from Public Library of Science
Bibliographic data for series maintained by plosntds ().